A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Phase 3 Completed 203 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability and the maintenance of effectiveness of a slow, extended-release oral formulation of paliperidone administered once daily to patients diagnosed with schizophrenia.

Timeline

Start: 2004-01
Primary completion: —
Completion: 2005-12

Publications

Kozma C, Dirani R, Canuso C, Mao L. Change in employment status over 52 weeks in patients with schizophrenia: an observational study. Curr Med Res Opin. 2011 Feb;27(2):327-33. doi: 10.1185/03007995.2010.541431. Epub 2010 Dec 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paliperidone	Unknown	3 mg	Oral
Subject	Paliperidone	Unknown	6 mg	Oral
Subject	Paliperidone	Unknown	9 mg	Oral
Subject	Paliperidone	Unknown	12 mg	Oral

A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications